Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) PT at $51.10

AnaptysBio, Inc. (NASDAQ:ANAB) has earned an average recommendation of “Moderate Buy” from the eleven analysts that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $51.10.

A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. lifted their target price on AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Truist Financial lifted their price target on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of AnaptysBio in a report on Wednesday, August 14th. Finally, Wedbush reaffirmed an “outperform” rating and set a $42.00 price target on shares of AnaptysBio in a report on Thursday, September 26th.

Insider Activity

In other news, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the sale, the insider now directly owns 15,398 shares of the company’s stock, valued at approximately $595,440.66. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, insider Eric J. Loumeau sold 8,720 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $39.82, for a total value of $347,230.40. Following the transaction, the insider now owns 7,020 shares in the company, valued at $279,536.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Paul F. Lizzul sold 1,500 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the transaction, the insider now owns 15,398 shares in the company, valued at $595,440.66. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 33,940 shares of company stock valued at $1,251,836. Insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

Institutional investors have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC acquired a new position in AnaptysBio in the 1st quarter valued at about $38,000. Headlands Technologies LLC increased its position in AnaptysBio by 444.8% in the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 2,900 shares during the period. China Universal Asset Management Co. Ltd. increased its position in AnaptysBio by 66.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 5,123 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 2,051 shares during the period. Duncan Williams Asset Management LLC acquired a new position in AnaptysBio in the 3rd quarter valued at about $282,000. Finally, Virtu Financial LLC acquired a new position in AnaptysBio in the 1st quarter valued at about $222,000.

AnaptysBio Trading Down 3.0 %

NASDAQ:ANAB opened at $33.98 on Friday. The firm has a market cap of $928.30 million, a PE ratio of -5.53 and a beta of -0.29. The stock has a fifty day moving average price of $35.45 and a 200 day moving average price of $28.50. AnaptysBio has a 12-month low of $13.36 and a 12-month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). The company had revenue of $10.97 million during the quarter, compared to analysts’ expectations of $25.85 million. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. Equities analysts forecast that AnaptysBio will post -6.84 EPS for the current year.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.